#United States #San Diego #Class Action #Robbins LLP #Aldeyra Therapeutics

Class Action Alert: Robbins LLP Investigates Aldeyra Therapeutics

Robbins LLP, a firm well-known for its focus on shareholder rights, is currently investigating allegations against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), concerning its claims about the effectiveness of its lead drug candidate. This investigation arises following the filing of a class action lawsuit meant to protect the interests of investors who purchased shares in Aldeyra between November 3, 2023, and March 16, 2026.

Aldeyra Therapeutics describes itself as a biotechnology company dedicated to discovering innovative therapies for immune-mediated diseases. The focus of this legal action is on reproxalap, a new reactive aldehyde species (RASP) inhibitor that the company has been studying as a potential treatment for various health conditions, primarily dry eye disease.

Allegations Against Aldeyra

According to court documents, the allegations center around statements made by Aldeyra that allegedly misled investors regarding the results of clinical trials for reproxalap. Specifically, the complaint claims that:

1. Inconsistent Trial Results: Aldeyra purportedly failed to disclose that the results from clinical trials involving reproxalap were not consistent. These inconsistencies raised significant concerns over the reliability of any purported positive outcomes from these trials.
2. Misleading Statements: The company's assertions about its business operations and prospects were claimed to be materially false and misleading, lacking a reasonable basis at all relevant times.

On March 17, 2026, Aldeyra filed a Form 8-K with the SEC, announcing that the company received a Complete Response Letter from the FDA regarding reproxalap. The letter indicated a lack of substantial evidence from adequately controlled studies that could support the drug's efficacy in treating the signs and symptoms of dry eye disease. This development dramatically impacted the company's stock price, causing it to fall by approximately 70.7%, closing at $1.24 per share the same day.

Next Steps for Investors

Investors who purchased Aldeyra securities during the specified period are encouraged to evaluate their potential eligibility to participate in the class action lawsuit. Those interested in acting as lead plaintiffs in the case can reach out to Robbins LLP. It's important to note that participating in the lawsuit is not a prerequisite for recovery, allowing those who opt to remain absent from the litigation to retain their rights as class members.

Robbins LLP operates on a contingency fee basis, meaning shareholders need not pay any upfront fees or expenses related to the class action.

About Robbins LLP

Since its establishment in 2002, Robbins LLP has been a recognized leader in shareholder rights litigation. The firm's commitment lies in advocating for shareholders, helping them recover from losses, and pushing for improved corporate governance practices. This ongoing dedication extends to holding company executives accountable for any wrongdoing.

If you would like to stay informed about developments in the class action against Aldeyra Therapeutics, or if you're interested in receiving alerts about corporate wrongdoing, you are encouraged to sign up for Stock Watch today.

For more information on how to engage with this situation or to discuss specific inquiries, you can directly contact attorney Aaron Dumas, Jr., or call Robbins LLP at (800) 350-6003 for assistance.

Conclusion

The allegations against Aldeyra Therapeutics highlight the importance of transparency and accountability in the biotech industry. As this class action progresses, investors are urged to stay informed and consider their options with the guidance of legal experts dedicated to protecting their rights.